- Home
- PHGE vs VBIO Comparison
PHGE vs VBIO Comparison
Compare PHGE & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHGE | VBIO |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 1.6M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PHGE | VBIO |
|---|---|---|
| Price | $0.14 | $2.91 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 22.2M |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 560.42 | N/A |
| EPS | ★ 3.56 | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $0.11 |
| 52 Week High | $8.50 | $4.14 |
Technical Indicators
Market Signals| Indicator | PHGE | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 61.18 |
| Support Level | N/A | $0.30 |
| Resistance Level | $0.21 | $4.14 |
| Average True Range (ATR) | 0.01 | 0.53 |
| MACD | 0.00 | 0.30 |
| Stochastic Oscillator | 2.02 | 69.73 |
Price Performance
Historical ComparisonAbout PHGE BiomX Inc. COmmon Stock
BiomX Inc is a company focused on acquiring and further developing technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response sectors. The Company's portfolio is built around the growing need for earlier and more accurate threat detection, particularly as UAVs and other autonomous systems play a larger role in defense and homeland security.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.